Form 4: O'Kane Kieran reports multiple insider transactions in BDSX

Rhea-AI Filing Summary

O'Kane Kieran reported multiple insider transaction types in a Form 4 filing for BDSX. The filing lists transactions totaling 3,784 shares at a weighted average price of $10.08 per share. Following the reported transactions, holdings were 9,469 shares.

Insider Trade Summary

Net Seller: 584 shares ($5,889)

Net Sell 4 txns

Insider O'Kane Kieran

Role Chief Commercial Officer

Sold 584 shs ($6K)

Type	Security	Shares	Price	Value
Sale	Common Stock	584	$10.0841	$6K
Exercise	Restricted Stock Units	73	$0.00	--
Exercise	Restricted Stock Units	1,527	$0.00	--
Exercise	Common Stock	1,600	$0.00	--

Holdings After Transaction: Common Stock — 8,885 shares (Direct); Restricted Stock Units — 0 shares (Direct)

Footnotes (1)

1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These RSUs vested in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Kane Kieran

(Last) (First) (Middle)

919 WEST DILLON RD

(Street)

LOUISVILLE CO 80027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		M		1,600	A	(1)	9,469	D
Common Stock	02/10/2026		S(2)		584	D	$10.0841(3)	8,885	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/09/2026		M			73	(4)	(4)	Common Stock	73	$0	0	D
Restricted Stock Units	(1)	02/09/2026		M			1,527(5)	(6)	(6)	Common Stock	1,527(5)	$0	1,526(5)	D

Explanation of Responses:

1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

3. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. These RSUs vested in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date.

5. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

6. These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

	/s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Biodesix (BDSX) report for Kieran O'Kane?

Biodesix reported RSU conversions into 1,600 common shares on February 9, 2026 and an open-market sale of 584 common shares on February 10, 2026. After these transactions, O'Kane directly held 8,885 shares of Biodesix common stock.

At what price were Biodesix (BDSX) shares sold in this Form 4 filing?

The 584 Biodesix common shares were sold at a weighted average price of $10.0841 per share. Footnotes explain the broker executed multiple trades between $9.94 and $10.21 to cover tax obligations arising from the vesting of restricted stock units.

How many Biodesix (BDSX) shares does Kieran O'Kane own after the reported transactions?

Following the RSU conversion and subsequent sale, Kieran O'Kane directly owns 8,885 shares of Biodesix common stock. This reflects the 1,600 shares received from RSU conversion and the 584 shares sold to satisfy tax withholding obligations related to the vesting event.

Were the Biodesix (BDSX) insider share sales discretionary or tax-related?

The filing states the 584 Biodesix common shares were sold automatically to cover taxes triggered by RSU vesting. A footnote clarifies these sales were executed by the issuer's broker specifically for tax withholding purposes, rather than as a discretionary open-market sale for portfolio rebalancing.

What do the restricted stock units (RSUs) in the Biodesix (BDSX) Form 4 represent?

Each restricted stock unit represents a contingent right to receive one Biodesix common share. The filing explains certain RSUs vest in sixteen quarterly installments from February 8, 2022, and others in four equal annual installments from February 8, 2023, generally subject to continued service.

How did Biodesix’s reverse stock split affect the RSU figures in this Form 4?

The Form 4 notes that RSU-related numbers were adjusted for a one-for-twenty reverse stock split effective September 15, 2025. This means the share amounts and RSU counts shown reflect post-split values, aligning the reported figures with the company’s current capital structure.